Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC starts two global studies with Brilique


Thursday, 28 Nov 2013 02:30am EST 

AstraZeneca PLC:Says it announced plans for two new Phase IIIb studies as part of PARTHENON, the company's clinical study with over 80,000 patients on Nov. 14.Says the studies are intended to provide a scientific understanding of Brilique (ticagrelor) tablets to more patients in different high-risk populations.Says it intends to implement both of these studies in Sweden in collaboration with Swedish healthcare.Says one study will compare ticagrelor with aspirin for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack (TIA).Says another study will compare ticagrelor with placebo over a long period for the prevention of major vascular events in patients with type 2 diabetes and high risk for cardiac / vascular disease. 

Company Quote

3781.5
23.0 +0.61%
17 Apr 2014